How many companies has Novartis AG acquired?

Novartis AG has made 5 documented acquisitions, with a combined disclosed deal value of $25.1B.

What was Novartis AG's first major acquisition?

Novartis AG's earliest documented acquisition in this dataset is Chiron Corporation in 2006.

What is Novartis AG's largest acquisition by deal value?

Novartis AG's largest acquisition by disclosed deal value is The Medicines Company in 2020, valued at $9.7B.

How much has Novartis AG spent on acquisitions in total?

Novartis AG has spent a combined disclosed total of $25.1B across its 5 documented acquisitions.

Novartis AG

PharmaceuticalsFounded 1996

Reviewed by Swet Parvadiya

Last reviewed: July 2026

Explore Novartis

Core profile pages, annual revenue records, and related research hubs for this company.

Novartis AG

PharmaceuticalsFounded 1996

Reviewed by Swet Parvadiya

Last reviewed: July 2026

Acquisitions

Novartis Acquisitions

Q: What is Novartis AG's most recent acquisition?

Novartis AG's most recent documented acquisition is MorphoSys AG in 2024. Novartis acquired MorphoSys for $2.9 billion to strengthen its oncology pipeline, specifically acquiring the anti-myelofibrosis drug pelabresib and the CD38 antibody MOR202..

Total Acquisitions

$25.1B

Disclosed Deal Value

MorphoSys AG

2024

$2.9B

Why

Novartis acquired MorphoSys for $2.9 billion to strengthen its oncology pipeline, specifically acquiring the anti-myelofibrosis drug pelabresib and the CD38 antibody MOR202.

Impact

The acquisition added late-stage oncology assets to the Novartis pipeline, providing potential new revenue streams in hematology and expanding the company's presence in the competitive myelofibrosis market.

Outcome

The integration is ongoing, with pelabresib advancing through Phase III trials. The acquisition demonstrates Novartis's strategy of buying de-risked, late-stage assets to fill pipeline gaps.

Chinook Therapeutics

2023

$3.5B

Why

Novartis acquired Chinook for $3.5 billion ($3.2B upfront + $300M milestones) to secure late-stage assets for rare kidney diseases, including atrasentan for IgA nephropathy.

Impact

The acquisition established Novartis as a leader in complement-mediated rare diseases, a therapeutic area with high unmet medical need and significant pricing power.

Outcome

Atrasentan has shown promising Phase III results, positioning it as a potential blockbuster drug for IgA nephropathy, a condition affecting hundreds of thousands of patients globally.

The Medicines Company

2020

$9.7B

Why

Novartis acquired The Medicines Company for $9.7 billion primarily to gain control of the cholesterol-lowering drug inclisiran, a small interfering RNA (siRNA) therapy.

Impact

The acquisition provided Novartis with a novel, long-acting cardiovascular therapy that can be administered twice a year, offering a significant convenience advantage over daily statins.

Outcome

The drug, now marketed as Leqvio, has achieved strong commercial success, generating significant sales growth and establishing Novartis as a leader in the siRNA therapeutic modality.

Advanced Accelerator Applications

2018

$3.9B

Why

Novartis acquired Advanced Accelerator Applications for $3.9 billion to establish a foothold in the emerging field of radioligand therapy for cancer.

Impact

This acquisition provided the foundation for Novartis's radioligand franchise, including the prostate cancer drug Pluvicto, which has become a major growth driver.

Outcome

Pluvicto generated $2.0 billion in FY2025 sales, validating the strategic rationale of the acquisition and establishing Novartis as the dominant player in the radioligand market.

Chiron Corporation

2006

$5.1B

Why

Novartis acquired the remaining stake in Chiron Corporation for $5.1 billion to gain full control of its vaccine and oncology businesses.

Impact

The acquisition significantly expanded Novartis's vaccine portfolio and added several oncology assets, including the breast cancer drug Femara.

Outcome

The integration was successful, and the acquired assets have contributed billions in revenue over the years, although Novartis later sold its influenza vaccine business to CSL in 2014.

Novartis AG's Growth & Acquisition Strategy

Novartis AG's growth strategy centers on this advantage: Novartis's advantage is a focused patented-medicine portfolio, global commercial reach, scale in clinical development, and specialty platforms such as radioligand therapy.

How Novartis AG Makes Money

Novartis makes money by discovering, developing, manufacturing, and commercializing patented medicines across cardiovascular, renal and metabolic, immunology, neuroscience, and oncology markets.

Related Companies

Eli Lilly and Company Novo Nordisk A/S Bausch Health Companies Inc.

Compare Novartis AG With Competitors

Novartis AG vs Eli Lilly and Company Novartis AG vs Novo Nordisk A/S Novartis AG vs Bausch Health Companies Inc.

Explore Novartis

Core profile pages, annual revenue records, and related research hubs for this company.